ArticleFrontiers in immunology2021
The Immune Landscape of Human Primary Lung Tumors Is Th2 Skewed.
Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 70 citations in OpenAlex.
- Convergent Microenvironment Linking Idiopathic Pulmonary Fibrosis and Lung Cancer.Expert reviews in molecular medicine · 2026Review
- HENMT1: an RNA methyltransferase in biology and disease.Journal of Zhejiang University. Science. B · 2026Review
- CAR T cells targeting CCR4 selectively deplete human Tregs ex vivo and in vivo.Blood advances · 2026Article
- CD44 upregulation in chronic liver disease marks the transition to hepatocellular carcinoma and portends poor prognosis.British journal of cancer · 2026Article
- A comprehensive study integrating bioinformatics analysis and experimental results on HROB as a potential biomarker for the prognosis of lung adenocarcinoma.Scientific reports · 2026Article
- The evolving role of the immune microenvironment of tumor draining lymph nodes in the development of biomarkers of non-small cell lung cancer.Frontiers in oncology · 2026Review
- Circulating cytokines as potential dynamic biomarkers of PD-1 blockade response and prognosis in non-small cell lung cancer.Frontiers in immunology · 2026Review
- In vitro models to mimic tumor endothelial cell-mediated immune cell reprogramming in lung adenocarcinoma.Journal of experimental & clinical cancer research : CR · 2025Article
- Development of retinoid nuclear receptor pathway antagonists through targeting aldehyde dehydrogenase 1A3.iScience · 2025Article
- Integrating genetic crosstalk between atherosclerosis and lung adenocarcinoma to advance precision diagnosis and treatment.Cell division · 2025Article
- Identification of a novel m6A RNA methylation regulator-based signature for prognosis and immune landscape prediction in hepatocellular carcinoma.Scientific reports · 2025Article
- Pan-cancer immune and stromal deconvolution predicts clinical outcomes and mutation profiles.Scientific reports · 2025Article
- Tumour and microenvironment crosstalk in NSCLC progression and response to therapy.Nature reviews. Clinical oncology · 2025Review
- Expression Characteristics and Prognostic Value of KLRG2 in Endometrial Cancer: A Comprehensive Analysis Based on Multi-Omics Data.Biomedicines · 2025Article
- Article
- Statistical analysis of spatial patterns in tumor microenvironment images.Nature communications · 2025Article
- Tissue levels of regulatory T cell related lncRNAs in lung cancer: evidence for dysregulation of immune responses.Discover oncology · 2025Article
- Immunogenic dying cells elicit potent anti-tumor T cell immunity against lung metastasis and tumorigenesis.Journal of cancer research and clinical oncology · 2025Article
- Article
- DCUN1D5 is a prognostic biomarker and correlated immune infiltrates and glycolysis in lung adenocarcinoma.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor-specific T helper (Th) cells have a central role in the immune response against cancer. However, there exist distinct Th cell subsets with very different and antagonizing properties. Some Th subsets such as Th1 protect against cancer, while others (Th2, T regulatory/Treg) are considered detrimental or of unknown significance (T follicular helper/Tfh, Th17). The Th composition of human solid tumors remains poorly characterized. Therefore, we established a four-color multiplex chromogenic immunohistochemical assay for detection of Th1, Th2, Th17, Tfh and Treg cells in human tumor sections. The method was used to analyze resected primary lung tumors from 11 patients with non-small cell lung cancer (NSCLC). Four microanatomical regions were investigated: tumor epithelium, tumor stroma, peritumoral tertiary lymphoid structures (TLS) and non-cancerous distal lung tissue. In tumor epithelium and stroma, most CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.